Somberg J C
Am Heart J. 1985 Feb;109(2):416-21. doi: 10.1016/0002-8703(85)90628-3.
The development of a group of calcium channel blockers that prolong the QT interval has raised interest in their possible proarrhythmic potential. In animal experiments lidoflazine has no observed arrhythmogenic potential and no antiarrhythmic potential in a model sensitive to the antiarrhythmic properties of both conventional and investigational agents. This lack of antiarrhythmic potential reduces the possible proarrhythmic potential even further, since it has been my observation that many of the more potent antiarrhythmic agents may facilitate arrhythmias in a considerable percentage of the most severely ill patients. Bepridil has both slow channel blocking properties and fast channel blocking effects and thus possesses an antiarrhythmic effect beyond the prolongation of repolarization. Even though early studies with humans showed the drug to be no more effective than the conventional reference agent procainamide, its potential cannot be fully assessed by these preliminary studies. The assessment of arrhythmogenicity is determined by use of the technique of PES. This technique has been shown effective in identifying patients with electrical instability and in identifying the effectiveness of antiarrhythmic agents in preventing VT and sudden death. Thus it seems probable that PES studies may be effective in predicting which drug or agent would facilitate arrhythmias. Alcohol, caffeine, cigarette smoke, and catecholamines facilitate PES induction of VT, lending support to the hypothesis that PES studies can be used to identify proarrhythmic drugs. In fact, patients who experience cardiac arrest on a class I agent can have VT provoked on that agent but not on antiarrhythmic drug therapy. PES thus identifies the proarrhythmic effect of the drug in that particular patient.(ABSTRACT TRUNCATED AT 250 WORDS)
一类可延长QT间期的钙通道阻滞剂的出现,引发了人们对其致心律失常潜在可能性的关注。在动物实验中,利多氟嗪在对传统药物和研究性药物的抗心律失常特性敏感的模型中,未观察到有致心律失常的可能性,也没有抗心律失常的作用。这种缺乏抗心律失常作用的情况,进一步降低了其致心律失常的潜在可能性,因为据我观察,许多效力更强的抗心律失常药物可能会在相当比例的重症患者中促发心律失常。苄普地尔兼具慢通道阻滞特性和快通道阻滞作用,因此除了延长复极外还具有抗心律失常作用。尽管早期人体研究表明该药物并不比传统参比药物普鲁卡因胺更有效,但这些初步研究并不能完全评估其潜力。致心律失常性的评估通过程序电刺激(PES)技术来确定。该技术已被证明在识别电不稳定患者以及确定抗心律失常药物预防室性心动过速和心脏性猝死的有效性方面有效。因此,PES研究似乎有可能有效预测哪种药物或制剂会促发心律失常。酒精、咖啡因、香烟烟雾和儿茶酚胺会促进PES诱发室性心动过速,这支持了PES研究可用于识别致心律失常药物的假说。事实上,在使用I类药物时发生心脏骤停的患者,使用该药物可诱发室性心动过速,但抗心律失常药物治疗时则不会。因此,PES可识别该特定患者中药物的致心律失常作用。(摘要截选至250词)